PDX Model Cohort
Hepatocelllular (HCC) PDX Models
Advance your hepatocellular carcinoma therapeutic candidates using a tumor bank of rare and meticulously curated HCC mouse models directly established from naïve and pretreated patient tumors.
Summary
Champions Oncology has developed a cutting-edge cohort of Hepatocellular Carcinoma -HCC mouse models, offering a comprehensive approach to liver cancer research. Our liver malignancy bank features 9* patient-derived xenograft (PDX) models, established from patient biopsies to preserve original molecular and clinical characteristics while minimizing genetic drift.
(*Model numbers fluctuate as our dataset continuously evolves.)
Champions' leading Hepatocellular Carcinoma cohort showcases primary models, each reflecting key clinical characteristics, mutations, and pretreatment history.
Access one of the largest banks of HCC mouse models with clinically relevant molecularand pathological characteristics on the market.
Includes models pretreated with advanced cancer therapies and those resistant to targeted treatments and the latest immunotherapies, kinase therapies, and more.
Access to highly characterized HCC models with High Complexity Flow Cytometry, WES, RNAseq, Proteomics, and Phosphoproteomics.
Features models retaining key mutation profiles and clinical cancer characteristics.
Clinically Relevant Models
Living & diverse bank of clinically relevant models that correlate with clinical outcomes
Pretreated PDX Models
Established from tumor biopsies from patients pretreated with latest generation therapies
Multi-omic Characterization
Clinical annotations coupled with molecular datasets and in vivo responses